Beleggen.nl Markt MonitorMarkt Monitor

BioPharma Terug naar discussie overzicht

INSM - Insmed - 2009 draadje

3.044 Posts
Pagina: «« 1 ... 75 76 77 78 79 ... 153 »» | Laatste | Omlaag ↓
  1. [verwijderd] 26 januari 2011 06:18
    Als ik mijn mening mag geven aan jullie ga snel van dit aandeel af. dit wordt weer tegen een lage prijs over genomen, aandeel houders keuren het goed, je geld wordt op je rekening gestort en we zijn klaar! Ik denk zonde van het geld! rendement 0! besteed je geld in betere aandelen!

    Het is goed om discussie's te voeren maar wat is het profijt? waar verdienen we als handelaren geld mee? Als dit aandeel potentie's had, heeft het nooit tot zover mogen komen! dit is gewoon weer verloren tijd! leuk dat jullie je zo verdiepen hierin maar het heeft weinig zin. mvg daytrader NASDAQ

  2. [verwijderd] 27 januari 2011 09:43

    Insmed Incorporated
    8720 Stony Point Parkway, Suite 200
    Richmond, Virginia 23235

    Telephone: (804) 565-3000

    January 26, 2011

    Dear Shareholder:

    You are cordially invited to attend a special meeting (the “Special Meeting”) of shareholders of Insmed Incorporated (the “Company” or “Insmed”) scheduled to be held on March 1, 2011, at 9:00 a.m. Eastern Standard Time, at the Doubletree Hotel, 4355 US Route 1, Princeton, NJ 08540.

    On December 1, 2010, we completed a business combination with Transave, Inc. (“Transave”), a privately-held, New Jersey-based biopharmaceutical company focused on the development of inhaled pharmaceuticals for the site-specific treatment of serious lung infections. As a result of the transaction, Transave was merged with and into our wholly owned subsidiary Transave, LLC.

    At the closing of the transaction, the former Transave stockholders received an aggregate of (i) 25,938,818 newly issued shares of our common stock, par value $0.01 per share (“Common Stock”), (ii) 91,745,892 shares of our newly created Series B Conditional Convertible Preferred Stock, par value $0.01 per share (the “Preferred Stock”), and (iii) approximately $561,280 in cash. A portion of the shares of Preferred Stock received by the former Transave stockholders was retained by Insmed to satisfy claims for indemnification under the merger agreement, if any.

    Shares of Preferred Stock are entitled to receive any dividends paid on our Common Stock (on an as-converted basis). Shares of Preferred Stock will begin to accrue additional dividends at a rate of 12.5% per annum at the end of each six month period following the earlier of (i) December 1, 2011 or (ii) the date upon which at least 50 patients have been given at least one dose in Phase III clinical trials for ARIKACE TM , but in no event earlier than September 1, 2011.

    Unless approval of our shareholders is received, shares of Preferred Stock are not convertible into shares of our Common Stock and are non-voting, except as a separate class with respect to certain actions. If shareholder approval is obtained, then all outstanding shares of Preferred Stock will automatically and immediately convert into shares of our Common Stock.

    At the Special Meeting, holders of shares of our Common Stock will be asked to consider and vote on a proposal to approve the conversion of the Preferred Stock into Common Stock and the issuance of shares of Common Stock upon conversion of the Preferred Stock (the “Preferred Stock Proposal”). Our Board of Directors unanimously recommends that our shareholders vote “FOR” the Preferred Stock Proposal.

    At the Special Meeting, holders of shares of our Common Stock will also be asked to consider and vote on a proposal to amend our Articles of Incorporation, as amended, to effect a one for 10 reverse stock split of the issued and outstanding shares of our Common Stock in order to reduce the number of outstanding shares of Common Stock (the “Reverse Split Proposal”). Our Board of Directors unanimously recommends that our shareholders vote “FOR” the Reverse Split Proposal.

    In addition, at the Special Meeting, holders of shares of our Common Stock may be asked to consider and vote on a proposal to adjourn the Special Meeting to solicit additional proxies if there are insufficient proxies at the Special Meeting to approve the Preferred Stock Proposal and/or the Reverse Split Proposal (the “Adjournment Proposal”). Our Board of Directors unanimously recommends that our shareholders vote “FOR” the Adjournment Proposal.

    All holders of record of our Common Stock as of January 25, 2011 are entitled to vote at the Special Meeting, provided that pursuant to the rules and regulations of the NASDAQ Capital Market, the shares of our Common Stock issued to former stockholders of Transave may not be voted on the Preferred Stock Proposal. Approval of the Preferred Stock Proposal requires the affirmative vote of a majority of votes cast, in person or by proxy, at the Special Meeting. Approval of the Reverse Split Proposal requires the affirmative vote of the holders of a majority of the issued and outstanding shares of our Common Stock. Approval of the Adjournment Proposal requires the affirmative vote of a majority of the shares of our Common Stock represented in person or by proxy at the Special Meeting whether or not a quorum is present.

    Please read the accompanying proxy statement for further information. It is important that your shares be represented and voted, regardless of the size of your holdings. Accordingly, whether or not you plan to attend the Special Meeting, please complete, sign and date and promptly return the enclosed proxy card in the self-addressed envelope enclosed for your convenience so that your shares will be represented at the Special Meeting. The proxy is revocable at any time before it is voted and will not affect your right to vote in person if you attend the Special Meeting.

    Thank you for your ongoing support of and continued interest in Insmed.

    Sincerely,

    /s/ Donald J. Hayden, Jr.

    Donald J. Hayden, Jr.
    Chairman of the Board

    Or.. you might want to consider why they are so confident that shareholders will be "happy" with the "deal" by then, that they would risk seeing a massive short attack between March 1st and June 15th to cause another delisting crisis!

    These VCs were not born yesterday.. I suspect they are well capable of seeing their investment here pay off handsomely! (And that would mean a share price well north of .71¢/share!)..

    And don't forget that Sharoky bought shares on the open market at .79¢ to 82¢/share.. I don't think he would be happy with anything less than a double, either!

    Sentiment : Strong Buy

  3. ludwig mack 27 januari 2011 18:01
    Reverse Split Proposal was dus toch niet uit de lucht komen vallen .........
    deze keer maakt het denk ik niet veel uit, omdat de intrinsieke waarde van het aandeel vooral of mede, net wat je wilt, door het cash dat ze hebben, naast de kno-how.

    gr
  4. [verwijderd] 1 februari 2011 21:07
    Tja, 58 centen. Het wordt tijd dat er eens iets gaat veranderen, bijvoorbeeld een serieuze overname door insm. Ik betwijfel echter of ze (het management) daar wel capabel voor zijn. De huidige strategie doet niets met de waarde van het aandeel. Gezapigheid en dood geld al ergggg lang.....
  5. [verwijderd] 17 februari 2011 19:59
    Form 8-K for INSMED INC

    --------------------------------------------------------------------------------

    17-Feb-2011

    Entry into a Material Definitive Agreement

    Item 1.01 Entry into a Material Definitive Agreement.
    On February 11, 2011 (the "Effective Date"), Insmed Incorporated ("Insmed") entered into a master services agreement (the "Agreement") with Chiltern International Inc. ("Chiltern"), a pharmaceutical development services provider. Under the terms of the Agreement, Chiltern will provide project management, clinical monitoring, data management and related services to Insmed in connection with the conduct of Phase III clinical studies of ArikaceTM (liposomal amikacin for inhalation) for treatment of cystic fibrosis ("CF") and nontuberculous mycobacteria ("NTM"). Pursuant to work orders to be entered into by Insmed and Chiltern, Insmed will pay Chiltern for such services as provided in each work order.

    The term of the Agreement is for five (5) years from the Effective Date. Insmed may terminate the Agreement or any work order at any time for any reason and without cause upon 30 days' prior written notice. Chiltern may terminate the Agreement or any work order at any time for any reason and without cause upon 120 days' prior written notice. In addition, either party may terminate the Agreement or any work order for a material breach of the Agreement by the other party by giving 30 days' prior written notice of termination if such breach is not cured within the 30 days notice period. If a work order is terminated by Insmed for reasons other than an uncured material breach by Chiltern or by Chiltern on account of a material breach by Insmed, Chiltern will be entitled to receive a termination fee. Except for the termination by Chiltern as a result of an uncured material breach by Insmed, in the event of termination of the Agreement or a work order, Chiltern is required to continue to perform work under the work order for four (4) months from the date of the termination notice during which Insmed will identify an alternate service provider.

    The Agreement provides for mutual representation and warranties and covenants by the parties. In addition, the Agreement requires the parties (i) to keep certain information confidential and (ii) to maintain certain insurance coverage. The Agreement also provides for an exclusivity commitment by Chiltern that it will not commence or actively seek to provide services to other third parties relating to the treatment of CF and NTM.

    Under the terms of the Agreement, Chiltern is obligated to indemnify Insmed against third party claims, damages and expenses arising out of a material breach of the Agreement by Chiltern or the negligence, recklessness, omissions or intentional misconduct of Chiltern. Similarly, Insmed is obligated to indemnify Chiltern against any third party claims, damages and expenses arising out of ArikaceTM, the Phase III clinical studies of ArikaceTM or the negligence, recklessness, intentional misconduct or breaches of the Agreement by Insmed, except to the extent that such claims, damages and expenses result from negligence, recklessness, intentional misconduct, omissions or breaches of the Agreement by Chiltern.

    Important Information

    Insmed filed a definitive proxy statement on January 26, 2011 with the Securities and Exchange Commission (the "SEC") to obtain shareholder approval (the "Shareholder Approval") (i) of the conversion of the Series B Conditional Convertible Preferred Stock issued to the former holders of preferred stocks of Transave, Inc. and the issuance of Insmed's common stock, par value $0.01 per share (the "Common Stock"), upon such conversion and (ii) to effect a one for 10 reverse stock split of Insmed's outstanding shares of Common Stock. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND OTHER RELEVANT MATERIALS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE SHAREHOLDER APPROVAL. The proxy statement, any amendments or supplements to the proxy statement and other relevant documents filed by the Insmed with the SEC are available free of charge through the web site maintained by the SEC at www.sec.gov or by calling the SEC at telephone number 1-800-SEC-0330. Free copies of these documents may also be obtained from Insmed's website at www.insmed.com or by writing to: Insmed Incorporated, 8720 Stony Point Parkway, Suite 200, Richmond, Virginia 23235, Attention: Mr. W. McIlwaine Thompson, Corporate Secretary.

    Insmed and its directors and executive officers are deemed to be participants in the solicitation of proxies from the shareholders of Insmed in connection with the Shareholder Approval. Information regarding Insmed's previous directors and executive officers is included in Insmed's definitive proxy statement for its 2010 annual meeting of stockholders held on June 9, 2010, which was filed with the SEC on April 30, 2010. Other information regarding the participants in such proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is included in the proxy statement filed in connection with the Shareholder Approval.

    Forward-Looking Statements

    This Current Report on Form 8-K contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this Current Report on Form 8-K, including statements relating to expectations regarding the anticipated benefits of the Agreement with Chiltern and the business strategies, plans and objectives of management, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, we may be unsuccessful in developing our product candidates, our expenses may be higher than anticipated and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2009 and Quarterly Report on Form 10-Q for the fiscal quarters ended March 31, 2010, June 30, 2010 and September 30, 2010. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this Current Report on Form 8-K. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Current Report on Form 8-K or to reflect the occurrence of unanticipated events.

    yok
  6. [verwijderd] 19 februari 2011 18:12
    quote:

    ludwig mack schreef op 18 februari 2011 21:45:

    dank voor plaatsen; waar haalde je het vandaan?
    geen p.b.

    gr
    Op de website kun je je email invullen, krijg je automatisch al het nieuws toegezonden!!!

    Grt yok
  7. [verwijderd] 19 februari 2011 20:57
    Waar is die crackedtooth toch gebleven? zal toch niet een paid pumper zijn geweest?? hij is ook niet meer op het yahoo forum verschenen. Wie weet meer!

    Yok

  8. [verwijderd] 19 februari 2011 22:24
    Re: Face it -Jlcinda
    Nice recap.

    I own a substantial amount of INSM shares and have for over 2 years. The wait for action was very frustrating but they did exactly what they said they were going to. We traded a NASDAQ listing and $120M cash for a drug which had very good PII results.

    The real issue here is how soon they can get through PIII and will the results mirror those of the PII trial. I believe that the drug is likely to be good and approvable but then you have to bring it through commercialization--think---sell out to bigger pharma with a hospital/physician based sales force.

    We may have $110M in cash now, but the trials will burn much of that. Assume that we get to the point in 2 years where we have $20-40M cash and PIII results are good. If the market for Arikase is $500M and you capture half of that, $250M in annual sales X 6 = $1.5B market cap. That roughly equates to about $6 in today's sharecount or $60 after the 1:10 RS. Roughly a 10x bagger.

    That's what I see as an upside provided all goes well. Will it happen? Can it happen? Depends if you're willing to wait 2-3 years to find out! I'd settle for half that in a year!

    GLTA,
    Creedster!

  9. ludwig mack 24 februari 2011 14:40

    Insmed to Participate on Phase III and Beyond Panel at 2011 RBC Capital Markets Healthcare Conference

    RICHMOND, Va., Feb. 24, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company, announced today that Timothy Whitten, President & CEO of Insmed, will participate on the Phase III and Beyond panel as part of the 2011 RBC Capital Markets Healthcare Conference, which will be held at the New York Palace Hotel in New York City, from Wednesday, March 2nd, through Thursday, March 3rd.

    The panel will be held at 9:00 AM ET on Thursday, March 3rd, and there will be a live audio webcast available at www.wsw.com/webcast/rbc129/rbc129.pan... The webcast will also be archived for 30 days.

    About Insmed

    Insmed Incorporated is a biopharmaceutical company focused on the development of innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases, and has a proprietary protein platform aimed at niche markets with unmet medical need. Insmed's primary focus is on the development of inhaled antibiotic therapy delivered via proprietary advanced pulmonary liposome technology in areas of high unmet need in lung diseases. For more information, please visit www.insmed.com.

    Forward-Looking Statements

    This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to the results of clinical trials, the development of our products, or the business strategies, plans and objectives of management, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, we may be unsuccessful in developing our product candidates, our expenses may be higher than anticipated and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2009 and Quarterly Report on Form 10-Q for the fiscal quarters ended March 31, 2010, June 30, 2010 and September 30, 2010. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

    Investor Relations Contact:


    Brian Ritchie - FD


    212-850-5683


    brian.ritchie@fd.com




    Media Contact:


    Irma Gomez-Dib - FD


    212-850-5761


    Irma.gomez-dib@fd.com

  10. ludwig mack 1 maart 2011 16:54
    Insmed Shareholders Approve Conversion of Series B Conditional Convertible Preferred Stock and Reverse Stock Split

    RICHMOND, Va., March 1, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company, announced today that Insmed's shareholders approved the proposal relating to the conversion of Insmed's Series B Conditional Convertible Preferred Stock (Series B Preferred Stock) into Insmed's Common Stock and the proposal relating to the one-for-10 reverse stock split of Insmed's Common Stock presented at the special meeting of its shareholders held today.

    As a result of the approval of the conversion of the Series B Preferred Stock, the 91,745,892 shares of Series B Preferred Stock outstanding were automatically and immediately converted into 91,745,892 shares of Insmed's Common Stock. In addition, Insmed intends to effect the one-for-10 reverse stock split as of the close of business on March 2, 2011 by filing an amendment to its Articles of Incorporation with the State Corporation Commission of the Commonwealth of Virginia. At the effective time of the amendment, each share of Insmed Common Stock issued and outstanding will automatically be reclassified and convert into 0.10 (1/10th) of a share of Insmed Common Stock.

    About Insmed

    Insmed Incorporated is a biopharmaceutical company focused on the development of innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases, and has a proprietary protein platform aimed at niche markets with unmet medical need. Insmed's primary focus is on the development of inhaled antibiotic therapy delivered via proprietary advanced pulmonary liposome technology in areas of high unmet need in lung diseases. For more information, please visit www.insmed.com.

    Forward-Looking Statements

    This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to expectations regarding the anticipated benefits of the conversion of Series B Preferred Stock and the reverse stock split and the business strategies, plans and objectives of management, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, we may be unsuccessful in developing our product candidates, our expenses may be higher than anticipated and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2009 and Quarterly Report on Form 10-Q for the fiscal quarters ended March 31, 2010, June 30, 2010 and September 30, 2010. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

    Investor Relations Contact:


    Brian Ritchie - FD


    212-850-5683


    brian.ritchie@fd.com


  11. ludwig mack 1 maart 2011 16:56
    Last Trade: 0.5201
    Trade Time: 10:37AM EST
    Change: Down 0.0249 (4.57%)
    Prev Close: 0.55
    Open: 0.53
    Bid: 0.5201 x 100
    Ask: 0.5202 x 700
    1y Target Est: 1.00
    Day's Range: 0.52 - 0.54
    52wk Range: 0.52 - 1.32
    Volume: 87,606
    Avg Vol (3m): 263,912
    Market Cap: 67.79M
    P/E (ttm): 43.35
    EPS (ttm): 0.01
    Div & Yield: N/A (N/A)
  12. [verwijderd] 1 maart 2011 17:26
    Mijn ervaring is dat een reverse split na de split altijd het in elkaar denderen van de koers tot gevolg heeft. Mijn probleem is dat ik niet wil verkopen....... Wat te doen.
  13. [verwijderd] 1 maart 2011 17:42
    Lekker blijven zitten, doe ik ook . Ik ben blij dat de conversie en de reverse split er door zijn .. Ik denk dat het nu langzamerhand omhoog gaat in plaats van naar beneden .. Let wel die 91 miljoen aandelen zijn er per direct bij . we traden nu ongeveer cash at hand en al het slechte nieuws is er nu wel uit. zoveel lager gaan we niet meer volgens mij. Misschien donderdag wel een positief PBtje om de koers te ondersteunen . Insmed is dan ook bij een conferentie Phase III and beyond
3.044 Posts
Pagina: «« 1 ... 75 76 77 78 79 ... 153 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.102
AB InBev 2 5.529
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.951
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.807
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.782
Aedifica 3 925
Aegon 3.258 323.007
AFC Ajax 538 7.088
Affimed NV 2 6.303
ageas 5.844 109.897
Agfa-Gevaert 14 2.062
Ahold 3.538 74.345
Air France - KLM 1.025 35.250
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.048
Alfen 16 25.107
Allfunds Group 4 1.514
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 409
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.638
AMG 971 134.102
AMS 3 73
Amsterdam Commodities 305 6.740
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.031
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.789
Arcelor Mittal 2.034 320.895
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.342
Aroundtown SA 1 221
Arrowhead Research 5 9.750
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.564
ASML 1.766 109.563
ASR Nederland 21 4.506
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.735
Axsome Therapeutics 1 177
Azelis Group 1 66
Azerion 7 3.439